Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection

Liver International

Volumn 30, Issue 3, 2010, Pages 479-486

  Kawaguchi, Takumi ^a   Taniguchi, Eitaro ^a   Morita, Yasuyo ^a,b   Shirachi, Miki ^a,c   Tateishi, Ikuo ^b   Nagata, Eisuke ^b   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Nagata Hospital   (Japan)

^c Chikugo City Hospital   (Japan)

Author keywords

Diabetes mellitus; Hepatitis C virus; Hepatocellular carcinoma; Insulin; Sulphonylurea

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLINIDE DERIVATIVE; GLITAZONE DERIVATIVE; INSULIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ARTICLE; CANCER INCIDENCE; CASE CONTROL STUDY; CAUSAL ATTRIBUTION; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENDER; HEPATITIS C; HUMAN; HYPOALBUMINEMIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; HEPATITIS C; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 77950610186     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02191.x     Document Type: Article

References (50)

1. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-9.
2. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago heart association detection project in industry. Am J Epidemiol 1990, 131:254-62.
3. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995, 273:1605-9.
4. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 2007, 16:83-9.
5. Pierce BL, Plymate S, Ostrander EA, Stanford JL. Diabetes mellitus and prostate cancer risk. Prostate 2008, 68:1126-32.
6. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-8.
7. Sumie S, Kawaguchi T, Komuta M. Significance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep 2007, 18:545-52.
8. Tazawa J, Maeda M, Nakagawa M. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002, 47:710-5.
9. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994, 21:1135-9.
10. Kawaguchi T, Yoshida T, Harada M. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004, 165:1499-508.
11. Romero-Gomez M, Del Mar Viloria M, Andrade RJ. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005, 128:636-41.
12. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006, 55:123-30.
13. Shintani Y, Fujie H, Miyoshi H. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004, 126:840-8.
14. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Hepatic iron accumulation may be associated with insulin resistance in patients with chronic hepatitis C. Hepatol Res 2007, 37:932-40.
15. Taura N, Ichikawa T, Hamasaki K. Association between liver fibrosis and insulin sensitivity in chronic hepatitis C patients. Am J Gastroenterol 2006, 101:2752-9.
16. Ihara Y, Toyokuni S, Uchida K. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes 1999, 48:927-32.
17. Sakowicz-Burkiewicz M, Kocbuch K, Grden M, Szutowicz A, Pawelczyk T. Diabetes-induced decrease of adenosine kinase expression impairs the proliferation potential of diabetic rat T lymphocytes. Immunology 2006, 118:402-12.
18. Barker BE, Fanger H, Farnes P. Human mammary slices in organ culture. I. Method of culture and preliminary observations on the effect of insulin. Exp Cell Res 1964, 35:437-48.
19. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996, 5:1013-5.
20. Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004, 127:1044-50.
21. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-8.
22. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-5.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27((Suppl. 1)):S5-10.
24. Bruix J, Sherman M, Llovet JM. Clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol 2001, 35:421-30.
25. Yoo HJ, Lee JM, Lee JY. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver. Invest Radiol 2009, in press, doi, 10.1097/RLI.0b013e3181bc271d
26. Wai CT, Greenson JK, Fontana RJ. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-26.
27. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the paris prospective study. Diabetes Care 2001, 24:843-9.
28. Saito K, Inoue S, Saito T. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002, 51:100-4.
29. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006, 53:87-94.
30. Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977, 64:536-7.
31. Schoen RE, Tangen CM, Kuller LH. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999, 91:1147-54.
32. Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World J Gastroenterol 2008, 14:5695-700.
33. Donadon V, Balbi M, Ghersetti M. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009, 15:2506-11.
34. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-76.
35. Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int 2009, 29:502-10.
36. Muto Y, Sato S, Watanabe A. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-13.
37. Wands J. Hepatocellular carcinoma and sex. N Engl J Med 2007, 357:1974-6.
38. Kath R, Schiel R, Muller UA, Hoffken K. Malignancies in patients with insulin-treated diabetes mellitus. J Cancer Res Clin Oncol 2000, 126:412-7.
39. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the scottish diabetes research network epidemiology group. Diabetologia 2009, 52:1755-65.
40. Formisano P, Oriente F, Fiory F. Insulin-activated protein kinase Cbeta bypasses Ras and stimulates mitogen-activated protein kinase activity and cell proliferation in muscle cells. Mol Cell Biol 2000, 20:6323-33.
41. Yao Y, Slosberg ED, Wang L. Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene 1999, 18:5159-66.
42. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002, 94:972-80.
43. Leroith D, Baserga R, Helman L, Roberts CT. Insulin-like growth factors and cancer. Ann Intern Med 1995, 122:54-9.
44. Giovannucci E. Nutrition, insulin, insulin-like growth factors and cancer. Horm Metab Res 2003, 35:694-704.
45. Kurtzhals P, Schaffer L, Sorensen A. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49:999-1005.
46. Hemkens LG, Grouven U, Bender R. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52:1732-44.
47. Jonasson JM, Ljung R, Talback M. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-54.
48. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-77.
49. Dejgaard A, Lynggaard H, Rastam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009, in press, doi, 10.1007/s00125-009-1568-4
50. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009, in press, doi, 10.1007/s00125-009-1530-5